Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03896633 · ClinicalTrials.gov registry record · Phase 1
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
A Phase 1 study of Glaucoma and Open Angle or Ocular Hypertension, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 637
- Enrollment target
- 1
- Study location
NCT03896633: Completed Phase 1 study of Glaucoma and Open Angle or Ocular Hypertension, sponsored by Bausch & Lomb Incorporated.
NCT03896633 is a Phase 1 study of Glaucoma and Open Angle or Ocular Hypertension that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 637 participants, below the 904-participant average among 92 other Glaucoma trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03896633, a Phase 1 study of Glaucoma and Open Angle or Ocular Hypertension, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 637 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide compared with AzoptTM
Conditions Studied
Interventions
- DRUG brinzolamide 1% ophthalmic suspension
- DRUG Azopt 1%
Study Locations (1)
New Jersey
- Various - Bridgewater
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 637 participants |
| Start Date | 2018-02-28 |
| Est. Completion | 2018-11-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03896633
The ClinicalTrials.gov registry entry for NCT03896633 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 637 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 904-participant average among 92 other Glaucoma trials with a reported enrollment target (30% lower). The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which brinzolamide 1% ophthalmic suspension is the first listed.
NCT03896633 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT03896633 about?
NCT03896633 is a clinical study titled "Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt". The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide compared with AzoptTM
What is the current status of trial NCT03896633?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 637 participants. The study started on 2018-02-28. Estimated completion is 2018-11-17.
What conditions does trial NCT03896633 study?
This clinical trial studies the following conditions: Glaucoma, Open Angle or Ocular Hypertension.
What interventions are being tested in trial NCT03896633?
The interventions under investigation include: brinzolamide 1% ophthalmic suspension (DRUG), Azopt 1% (DRUG).
Who is sponsoring clinical trial NCT03896633?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03896633 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Topical Insulin for Glaucoma
RECRUITING · Phase 1
-
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
ACTIVE NOT RECRUITING · Phase 1
-
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
ACTIVE NOT RECRUITING · Phase 1
-
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
COMPLETED · Phase 1
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
COMPLETED · Phase 1
-
Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
COMPLETED · Phase 1
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.